Oral Presentations to Highlight Results of Customer Collaborations using the ECO Synthesis™ Platform Oral Presentations to Highlight Results of Customer Collaborations using the ECO Synthesis™ Platform
Go here to see the original:
Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting
CARSON CITY, Nev., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of its previously announced registered direct offering of 2,667,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.25 per share.
More:
BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement
CARLSBAD, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- CarnoSyn® Brands and parent company Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), are pleased to announce a new distribution partnership with B&D Nutritional Ingredients, Inc., a renowned raw material distributor in the dietary supplement industry since 1993. This strategic partnership took effect on October 1st, 2024.
Continue reading here:
CarnoSyn® Brands Announces New U.S. Distribution Agreement With B&D Nutritional Ingredients
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, today announced the pricing of its upsized initial public offering of 16,000,000 shares of its common stock at a public offering price of $18.00 per share. In addition, Septerna has granted the underwriters a 30-day option to purchase up to an additional 2,400,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by Septerna, and the common stock is expected to begin trading on the Nasdaq Global Market on October 25, 2024, under the ticker symbol “SEPN.”
View original post here:
Septerna Prices Upsized Initial Public Offering
Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance
Read the original:
Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong...
First clinical results for RMC-9805, a RAS(ON) G12D-selective inhibitor, demonstrate encouraging tolerability and antitumor activity in patients with PDAC
VANCOUVER, British Columbia, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced new preclinical data for Zymeworks’ antibody-drug conjugate (ADC) candidates ZW220 and ZW251 in presentations at the European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR) Conference taking place in Barcelona on October 23-25, 2024.
PRINCETON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched Estradiol Gel, 0.06%. ANI’s Estradiol Gel, 0.06% is the generic version of the reference listed drug (RLD) EstroGel® Gel, 0.06%.
See the rest here:
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.06%
TEL AVIV, Israel, Oct. 25, 2024 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced an abstract including interim results from ENLIGHTED, the Company’s ongoing Phase 3 study of Padeliporfin VTP treatment of patients with low-grade upper tract urothelial cancer (UTUC), will be presented at the 16th European Multidisciplinary Congress on Urological Cancers (EMUC 2024) taking place November 7 – 10, 2024, in Lisbon, Portugal.
Originally posted here:
ImPact Biotech to Present Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at EMUC 2024
NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report third quarter 2024 financial and operating results before the market open on Friday, November 8, 2024. The Company will hold a conference call and webcast to discuss these results at 8:00 a.m. ET.
Visit link:
Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast